Gastrointestinal hormones and weight management

The Lancet

Volumn 374, Issue 9701, 2009, Pages 1570-1571

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PLACEBO; TETRAHYDROLIPSTATIN;

ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; DRUG MECHANISM; FOOD INTAKE; HUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HUMANS; LACTONES; OBESITY; WEIGHT LOSS;

EID: 70350622050     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61560-9     Document Type: Note

References (10)

1. Chaudhri O.B., Field B.C., and Bloom S.R. Gastrointestinal satiety signals. Int J Obes (Lond) 32 suppl 7 (2008) S28-S31
2. Cummings D.E., and Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 117 (2007) 13-23
3. Astrup A., Rössner S., Van Gaal L., et al., on behalf of the NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 10.1016/S0140-6736(09)61375-1 published online Oct 23.
4. Rucker D., Padwal R., Li S.K., Curioni C., and Lau D.C.W. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335 (2008) 1194-1199
5. Vray M., Joubert J.M., Eschwage E., et al. Results from the observations study EIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat. Therapie 60 (2005) 17-24
6. Patriti A., Facchiano E., Sanna A., Gullà N., and Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 14 (2004) 840-848
7. Verdich C., Flint A., Gutzwiller J.-P., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 (2001) 4382-4389
8. Lovshin J.A., and Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5 (2009) 262-269
9. Stonehouse A., Okerson T., Kendall D., and Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 4 (2008) 101-109
10. Buse J.B., Rosenstock J., Sesti G., et al., for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 (2009) 39-47